Shares of Blueprint Medicines Corp. (BPMC) soared 26.6% to $91 in premarket trading on Monday, Dec. 11, after the Cambridge, Mass.-based firm on Sunday unveiled new data from its ongoing Phase 1 study of avapritinib (formerly known as BLU-285) in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting and Exposition (ASH) in Atlanta.
The data from the dose escalation part of the study "showed strong clinical activity regardless of advanced SM subtype, prior treatment with midostaurin or the presence of additional mutations," the company said.
Also at ASH, Spark Therapeutics Inc. (ONCE) on Monday reported preliminary data from the Phase 1/2 study of SPK-8011 in hemophilia A.
"While still early in the dose-escalation clinical trial of SPK-8011, we are encouraged these data show clinically significant reductions in ABR and AIR with no serious adverse events reported to date," said Katherine A. High, president and head of research and development at Spark, in a statement.
In addition, Spark and Pfizer Inc. (PFE) on Monday unveiled longer-term preliminary data from the ongoing Phase 1/2 study of SPK-9001 in hemophilia B.
"Now, with four participants followed for more than 18 months, we continue to see consistent levels of factor IX activity, no serious adverse events, as well as a sustained reduction in both the symptoms of hemophilia and the prophylactic and disease management protocols that were used prior to infusion with SPK-9001," High said in a statement.
Shares of Spark were trading at $48.55, down 33.8%. Shares of Pfizer were changing hands at $35.75, up 0.03%.
Among the other the stock movers was bluebird bio Inc. (BLUE) , up 30% to $222.70. The Cambridge, Mass.-based firm made a string of announcements at ASH, including its Monday presentation of updated data from its HGB-205 study of its LentiGlobin gene therapy product candidate in patients with severe sickle cell disease and transfusion-dependent β-thalassemia.
More of What You Should Be Reading on Real Money: